Intel launched the Intel Core processor Series 2 with P-cores, a platform engineered for mission-critical edge applications. Intel also announced its latest Edge AI suite for Health & Life Sciences, providing validated reference pipelines and benchmarking tools for AI-powered patient monitoring solutions.

Intel Core Series 2 processors address the critical challenges facing modern industrial operations, which demand processors that can handle multiple critical workloads simultaneously—from safety-critical control systems to real-time data processing, whilst maintaining precise timing and deterministic performance. Traditional processors often force manufacturers to choose between computational power and real-time reliability, leading to complex multi-processor architectures that increase costs and system complexity.

The Intel Health & Life Sciences AI Suite focuses on AI-enabled patient monitoring. As healthcare systems face growing patient volumes and staffing constraints, patient monitoring is evolving from isolated devices to intelligent, connected ecosystems that demand AI-enabled solutions for earlier insights and reliable real-world operation. The suite showcases concurrent, multimodal workloads running locally on Intel processors, including AI-based electrocardiogram (ECG) arrhythmia detection, remote photoplethysmography, and anonymous
3D visual tracking—helping original equipment manufacturers (OEMs), original design manufacturers (ODMs), and independent software vendors (ISVs) evaluate platforms using representative scenarios rather than synthetic benchmarks.

The edge systems powered by Intel Core Ultra Series 3 and Intel Core Series 2 with P-cores are available now.